News headlines about Applied Genetic Technologies (NASDAQ:AGTC) have been trending somewhat positive recently, Accern Sentiment reports. Accern identifies positive and negative news coverage by reviewing more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Applied Genetic Technologies....More>>>
A revolutionary technology and only a handful of stocks you can buy to profit from it.
That’s the scenario for gene editing, a scientific breakthrough that holds the promise to radically change how diseases are treated. You can count the number of gene-editing stocks currently available on both hands and still have fingers to spare.
One of the top gene-editing stocks on the market....More>>>
Today, more than 5 million Americans suffer from Alzheimer’s disease, and millions more will be diagnosed in the years to come.
But those days could soon be over.
I’ve discovered companies working on a new treatment that has the potential to do much more than just mask Alzheimer symptoms.
If this new treatment lives up to its promise, it could deliver incredible profits....More>>>
News coverage about CytRx (NASDAQ:CYTR) has trended somewhat positive this week, Accern Sentiment reports. Accern ranks the sentiment of media coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. CytRx earned a news sentiment score of 0.17 on....More>>>
At the beginning of the week, our Under the Radar Movers newsletter suggested small cap development-stage biotech stock Heat Biologics Inc (NASDAQ: HTBX) as a long trade:
“To really appreciate the potential upside of Heat Biologics, we have to take a step back and look at it from a distance. As you can see, while the July/August surge spent the next two months cooling off, the technical....More>>>
Did you miss “Mad Money” on CNBC? If so, here are some of Jim Cramer’s top takeaways.
In an “Executive Decision” segment, Cramer sat down with Dan Browne, co-founder, president and CEO of Revance Therapeutics (RVNC) , the biotech that’s actively developing an alternative to Allergan’s (AGN) wildly successful Botox.
Browne said that....More>>>
Jim Cramer shares his views every day on RealMoney. Click here for a real-time look at his insights and musings.
Cramer: Why Are These Stocks Doing Well?
Posted at 7:17 p.m. EDT on Thursday, Nov. 17, 2016
Sometimes you just want to keep a list of stocks that act too well. At the top of the list? Celgene (CELG) . This company had a very good quarter with lots of growth but has....More>>>
Amyris Biotechnologies (NASDAQ: AMRS) and Gevo (NASDAQ:GEVO) are both small-cap basic materials companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, dividends, analyst recommendations, risk, institutional ownership, earnings and valuation.
Valuation & Earnings
Get Amyris Biotechnologies alerts:....More>>>
This time last year, Renewable Energy Group (NASDAQ:REGI) and Codexis (NASDAQ:CDXS) were each valued at around $500 million. While both businesses sport a market cap in excess of $1 billion today after an impressive rise last year, they’re still considered small-cap stocks. Judging from recent and expected full-year 2018 operating results, both would make great additions to your portfolio....More>>>
Media stories about Stellar Biotechnologies (NASDAQ:SBOT) have been trending somewhat positive recently, Accern Sentiment reports. Accern ranks the sentiment of press coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Stellar Biotechnologies....More>>>